Macromolecular approaches to prevent thrombosis and intimal hyperplasia following percutaneous coronary intervention

Biomacromolecules. 2014 Aug 11;15(8):2825-32. doi: 10.1021/bm5007757. Epub 2014 Jul 8.

Abstract

Cardiovascular disease remains one of the largest contributors to death worldwide. Improvements in cardiovascular technology leading to the current generation of drug-eluting stents, bioresorbable stents, and drug-eluting balloons, coupled with advances in antirestenotic therapeutics developed by pharmaceutical community, have had a profound impact on quality of life and longevity. However, these procedures and devices contribute to both short- and long-term complications. Thus, room for improvement and development of new, alternative strategies exists. Two major approaches have been investigated to improve outcomes following percutaneous coronary intervention including perivascular delivery and luminal paving. For both approaches, polymers play a major role as controlled research vehicles, carriers for cells, and antithrombotic coatings. With improvements in catheter delivery devices and increases in our understanding of the biology of healthy and diseased vessels, the time is ripe for development of novel macromolecular coatings that can protect the vessel lumen following balloon angioplasty and promote healthy vascular healing.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Coronary Restenosis* / etiology
  • Coronary Restenosis* / metabolism
  • Coronary Restenosis* / pathology
  • Coronary Restenosis* / prevention & control
  • Drug-Eluting Stents*
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Hyperplasia
  • Percutaneous Coronary Intervention / adverse effects*
  • Postoperative Complications* / metabolism
  • Postoperative Complications* / pathology
  • Postoperative Complications* / prevention & control
  • Thrombosis* / etiology
  • Thrombosis* / metabolism
  • Thrombosis* / pathology
  • Thrombosis* / prevention & control
  • Tunica Intima* / metabolism
  • Tunica Intima* / pathology

Substances

  • Fibrinolytic Agents